Fig. 4

The dsDNA@DMONs induced the activation of type I interferon signaling and enhanced the antigen presentation ability of tumor cells. A RT-qPCR analysis of the gene expression of Ifnb, Cxcl10, and Isg15 in marine cell lines MC38, B16-F10, 4T1, Panc02 treated with PBS, DMONs (Si: 6 μg/mL), dsDNA (2.4 μg/mL) or dsDNA@DMONs (Si: 6 μg/mL) for 24 h; and IFNB, CXCL10, and ISG15 in human cell lines MDA-MB-231 and A375 treated with PBS, DMONs (Si: 6 μg/mL), dsDNA (2.4 μg/mL) or dsDNA@DMONs (Si: 6 μg/mL) for 24 h. B RT-qPCR analysis of the gene expression of Ifnb, Cxcl10, and Isg15 in B16-F10 treated with the indicated concentration of dsDNA@DMONs for 24 h. C Western blot of p-TBK1 in B16-F10 cells treated with PBS, DMONs (Si: 6 μg/mL), dsDNA (2.4 μg/mL) or dsDNA@DMONs (Si: 6 μg/mL) with or without H-151 (2 μM) for 24 h. GAPDH serves as a loading control. D RT-qPCR analysis of the gene expression of B2m, Psmb5, Tap1, Tap2, and Tapbp in B16-F10 cells treated with PBS, DMONs (Si: 6 μg/mL), dsDNA  (2.4 μg/mL) or dsDNA@DMONs (Si: 6 μg/mL) for 24 h. Data are shown as mean ± SEM (n ≥ 3). P value was calculated by unpaired Student's t-test in A, B and D. (*p < 0.05; **p < 0.01; ***p < 0.001)